Outcome of the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited in…
As filed · Outcome of the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited in terms of the provisions of Regulation 30 of the Securities and Exchange Board of India (Listi
What happened
FactThe Company approved a Corrigendum to the Extraordinary General Meeting (EGM) Notice for a meeting scheduled on August 05, 2026, to seek member approval for a proposed Preferential Issue of Fully Convertible Warrants. Modifications were made in response to queries from the National Stock Exchange of India Limited and BSE Limited, but all other contents of the EGM Notice remain unchanged. The meeting was held on July 29, 2026, and concluded shortly after.
Why it matters
CapitSignal interpretationShares are issued to named investors at a set price, diluting existing holders and changing who sits on the register.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedIn the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Change
FactImplication
CapitSignal interpretationGuidance
RevisedLooking ahead, on the domestic side we are focused on expanding our ethical footprint into peninsular India and into high-growth chronic therapeutic categories, targeting 15-20% CAGR growth in this business.
We expect FY27 to witness revenue growth of more than 50%.
Change
FactImplication
CapitSignal interpretationGuidance
WithdrawnFY30 is very long way to go, but yes, we would look for a revenue of minimum ₹1500 crores of a revenue and maybe a net profit of approx ₹200 plus.
We may revise this. We don't want to overproject and want to say that we'll do this one year in advance. But by the end of the financial year, we'll revisit all these numbers.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Who the allottees are
- Issue price versus market price
- Lock-in period on the new shares
- We expect FY27 to witness revenue growth of more than 50%. (management committed by FY27)
- A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partner (management committed by FY27)
Evidence
- Exchange filing(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- PREFERENTIAL_ALLOTMENT base 66; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%